Orchestra BioMed (OBIO) to Release Earnings on Monday

Key Points

• Orchestra BioMed is expected to report its Q2 2025 earnings on August 11, with analysts forecasting a loss of ($0.51) per share.
• In its last quarter, the company posted a loss of ($0.49) per share, falling short of the consensus estimate of ($0.46).
• Current institutional ownership stands at 53.20%, with Bank of America recently increasing its stake by 42.0%.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). Orchestra BioMed had a negative return on equity of 189.26% and a negative net margin of 2,297.85%. The business had revenue of $0.87 million for the quarter, compared to the consensus estimate of $0.39 million. On average, analysts expect Orchestra BioMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Orchestra BioMed Price Performance

Shares of NASDAQ OBIO traded up $0.09 during trading on Friday, reaching $2.69. The company had a trading volume of 364,961 shares, compared to its average volume of 291,022. The business's 50 day moving average price is $3.04 and its 200-day moving average price is $3.60. The company has a debt-to-equity ratio of 0.85, a quick ratio of 3.34 and a current ratio of 3.35. The stock has a market cap of $103.94 million, a PE ratio of -1.51 and a beta of 0.62. Orchestra BioMed has a 52 week low of $2.37 and a 52 week high of $7.04.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on OBIO. Chardan Capital reissued a "buy" rating and issued a $20.00 target price on shares of Orchestra BioMed in a research report on Thursday. Barclays cut their price target on Orchestra BioMed from $16.00 to $12.00 and set an "overweight" rating for the company in a research note on Monday, May 5th. Finally, HC Wainwright reissued a "buy" rating on shares of Orchestra BioMed in a research note on Wednesday, April 23rd. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Orchestra BioMed presently has an average rating of "Buy" and a consensus target price of $14.00.

Insider Activity at Orchestra BioMed

In other Orchestra BioMed news, insider David P. Hochman acquired 20,000 shares of Orchestra BioMed stock in a transaction dated Monday, August 4th. The stock was purchased at an average cost of $2.75 per share, for a total transaction of $55,000.00. Following the completion of the acquisition, the insider directly owned 349,331 shares of the company's stock, valued at $960,660.25. This represents a 6.07% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Orchestra BioMed

An institutional investor recently raised its position in Orchestra BioMed stock. Bank of America Corp DE raised its position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) by 42.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,780 shares of the company's stock after purchasing an additional 7,036 shares during the period. Bank of America Corp DE owned 0.06% of Orchestra BioMed worth $95,000 at the end of the most recent reporting period. 53.20% of the stock is owned by hedge funds and other institutional investors.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.